Lexaria Bioscience progresses with hypertension and oral nicotine studies using DehydraTECH

Lexaria Bioscience Corp. (NASDAQ:LEXX) CEO Chris Bunka tells Proactive's Stephen Gunnion about the company's patented drug delivery technology, DehydraTECH, which improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. Bunka says a recent human clinical study using its patented DehydraTECH-CBD capsule formulation may be the world's first to evidence a sustained drop in blood pressure in normally active hypertensive patients following multiple weeks of oral cannabidiol therapy. In addition, Independent Review Board approval has now been received for human clinical nicotine study NIC-H22-1, with human dosing to begin soon, he adds. #ProactiveInvestors #LexariaBioscience #DehyrdraTECH #Nasdaq